Fungit Biosolutions

**Product and the concrete problem it solves.** Fungit Biosolutions is developing biological crop-protection products for two linked failure points in the food system: disease and abiotic stress while a crop is growing, and fungal spoilage after harvest. The company describes its mission as improving food security by extending fruit and vegetable shelf life and improving crop yield. That is a practical problem rather than a purely environmental one. Growers lose saleable output to plant pathogens, heat, drought, salinity, and other stresses; packers and distributors lose additional output during storage and transport; and chemical-residue rules are narrowing the set of conventional tools that can be used in some markets. Fungit says 20-40% of agricultural produce is wasted through post-harvest spoilage, a company-cited estimate that should be treated as directional rather than independently audited. Its intended intervention is a biological layer that helps crops and produce resist disease without requiring a synthetic pesticide for every application. The company has publicly shown treated lemons with inhibited Penicillium infection and extended shelf life, and seedlings treated with endophytes that are intended to stimulate growth. These examples indicate the product strategy, but they do not yet establish broad field efficacy across crops, climates, or commercial supply chains.

**Core technology and how it works.** Fungit’s platform starts with microorganisms rather than a conventional small-molecule active ingredient. The company says it screens and isolates fungal biocontrol species and maintains biobanks sourced from plants that adapted to harsh environments, including drought, extreme heat, and high salinity. The underlying logic is that organisms surviving those stresses may carry useful biological interactions that can be transferred into agricultural formulations or plant-associated treatments. Fungit’s public description also names microbiology, genome sequencing, bioinformatics, and tailored biocontrol-agent development as parts of the R&D workflow. In its pre-harvest concept, beneficial microorganisms are intended to associate with plant tissues, strengthen host-defense responses, and reduce susceptibility to pathogenic fungi or climate-related stress. In its post-harvest concept, the treatment is intended to inhibit decay organisms on harvested produce and slow the loss of marketable quality. The company has used the phrase “probiotics for plants” to make the mechanism accessible, but the commercial diligence question is much more exact: which strains, metabolites, colonization behaviors, formulations, and application protocols produce a repeatable result, and can those results survive scale-up, storage, regulatory testing, and variable farm conditions?

**Market, customers, and go-to-market.** Fungit is targeting a large but demanding agricultural-input market with multiple possible entry points. Its own public materials identify large agrochemical manufacturers and distributors such as Bayer, Syngenta, and Decco as potential strategic customers, while growers, nurseries, seed producers, and packing houses are potential tactical customers. That two-level model is sensible for a small company: direct pilots can generate crop and shelf-life evidence with growers and packers, while a strategic licensing, formulation, or distribution relationship could provide regulatory expertise and geographic reach. The company has said it is moving from laboratory work into semi-commercial studies with potential partners and previously expected market entry toward the end of 2026. Its location in Israel’s Negev agrifood ecosystem is also part of the go-to-market logic. Fungit has described the region as offering farmers, packing houses, academic expertise, and agricultural laboratories that can support validation. The commercial challenge is that biological inputs are not sold on a laboratory result alone. Buyers need consistent performance, a clear mode of action, shelf stability, compatibility with integrated pest management, easy field application, and a cost per treated hectare or kilogram of produce that works within existing farming economics.

**Traction, funding, and third-party validation.** The public record supports an early technical-validation story, not a scaled commercial one. CTech reported in November 2023 that Fungit had raised $500,000, with InNegev and the Israel Innovation Authority identified as the investors or support bodies, and that its development work had achieved proof of concept before moving into semi-commercial studies. The same coverage described a planned $2.5 million raise to reach a commercial-sales milestone; no completed later equity round is confirmed in the sources reviewed for this record. The Israel Innovation Authority currently lists Fungit Biosolutions as an Israeli agritech company established in 2021, with eight employees, R&D-stage status, and support through its Periphery Entrepreneurship Incubators, Startup Fund, and Horizon Europe-related programs. CTech’s 2023 profile gives a different founding year, 2022, and described three employees plus two consultants at that time, so the record preserves the discrepancy rather than presenting a false precision. Fungit’s official site says it was selected for the 2024 EIT Food Accelerator Network, and EIT Food’s Tech4RegenAg page lists Fungit among the 2026 program finalists. These are meaningful ecosystem and technical-validation signals, but they are not substitutes for regulatory approvals, independently replicated field trials, repeat orders, or disclosed revenue.

**Founders and team background.** Fungit was founded by Dr. Liat Avrahami-Moyal and Dr. Shimon Lecht, with Gal Admati serving as CEO and Hala Alqrenawi identified by the company as a biotechnology engineer and R&D lead. Avrahami-Moyal brings the most directly relevant technical profile disclosed publicly: the company and CTech describe roughly twelve years of microbiology and phytopathology R&D experience, including management of laboratory work on biological solutions for plant disease. Lecht is described as having approximately fifteen years of experience leading biotech and pharmaceutical startups from concept through market, including work on formulations, scale-up, fundraising, and transactions. Admati’s background combines a B.Sc. and MBA with scientific-management and commercialization experience; before becoming Fungit’s CEO, he was associated with the InNegev incubator and had prior program-management roles in medical technology. Alqrenawi adds biotechnology-engineering capacity and represents the company’s effort to build a scientific team in the Negev. The team composition is well matched to an early agricultural-biotech program because it combines pathogen biology, product development, and commercialization. The open diligence gap is organizational depth: public materials do not establish the current laboratory headcount beyond the Innovation Authority’s eight-person figure, nor do they document a large regulatory, formulation, field-trial, or international sales organization.

**Competitive dynamics.** Fungit competes in a category where the substitute is not one company but a stack of established chemical, biological, and operational practices. Large crop-protection companies such as Bayer and Syngenta bring regulatory infrastructure, distribution, farmer relationships, and broad portfolios that can bundle conventional and biological products. Biological specialists such as Novozymes and BioWorks compete through microbial products, formulation know-how, and channel access. Post-harvest alternatives include fungicidal washes, cold-chain controls, packaging interventions, and improved logistics, while pre-harvest alternatives include resistant varieties, synthetic fungicides, integrated pest management, and precision-agriculture monitoring. Fungit’s proposed edge is the combination of stress-adapted microorganism discovery, host-associated biology, pre- and post-harvest applicability, and a potentially lower-residue profile. That could create a differentiated product if a strain works across commercially important crops and remains stable in a manufacturable formulation. It is not yet a defensible moat on public evidence. The key tests are strain uniqueness and freedom to operate, reproducible efficacy against target pathogens, performance under real weather and supply-chain conditions, formulation and fermentation economics, regulatory timing, and whether incumbents become customers or simply reproduce the concept internally. Fungit’s own framing that large agrichemical companies may be strategic partners is strategically plausible, but it also highlights the risk of dependence on a powerful downstream channel.

**Defense, security, and resilience dual-use relevance.** Fungit’s dual-use relevance is strongest through food-system resilience, not through a direct defense product. Reliable crop protection and post-harvest preservation reduce the vulnerability of communities, military provisioning chains, humanitarian operations, and import-dependent regions to crop disease, climate stress, transport disruption, and sudden loss of local production. A biological treatment that extends shelf life can reduce the amount of food, refrigeration, and replacement inventory required to sustain distributed populations; a treatment that improves yield or stress tolerance can make agricultural production more robust in water-constrained or heat-exposed environments. The Negev setting also matters as a resilience signal: CTech documented that Fungit’s Rahat and Gilat-area operations were disrupted by the security situation after October 7, while the team continued development and sought alternative operating arrangements. That is evidence of exposure to a national-resilience context, not evidence of a defense contract. No reviewed source establishes military procurement, classified work, defense trials, or a government food-security program. The appropriate assessment is therefore dual-use at the core technology and mission level, with civilian agriculture as the current market and resilience, emergency food supply, and strategic-agriculture applications as credible but unfielded extensions. Any government or defense deployment would also require biosafety, environmental, regulatory, and supply-chain diligence.

**Growth stage, trajectory, and key diligence risks.** Fungit is classified as early stage because the available evidence shows an R&D company moving from proof of concept toward semi-commercial validation, not a company with disclosed production revenue or mature distribution. Its trajectory depends on converting a promising microbial library and initial laboratory demonstrations into approved, stable, affordable products that work outside controlled conditions. The first milestones to monitor are named field or packing-house studies, results by crop and pathogen, product-registration progress in Israel or an export market, formulation shelf life, manufacturing partner selection, and a completed financing round that funds the path to commercialization. The main risks are: (1) biological variability across cultivars, soils, climates, and post-harvest handling; (2) long and country-specific regulatory approvals for biocontrol products; (3) formulation, fermentation, storage, and application economics; (4) false positives or inconsistent protection that could damage grower trust; (5) limited capital and small-team execution risk; (6) competition from biological and incumbent agrichemical portfolios; and (7) a mismatch between the strategic food-security narrative and the willingness of farmers or distributors to pay for measurable incremental yield or shelf life. The public evidence justifies active monitoring of a technically interesting Israeli food-security startup, while its score remains capped until independent field performance, regulatory progress, commercial partnerships, and recurring sales are visible.